Reentering this trade (original: https://tradingview.sweetlogin.com/chart/AGL/FkmqxQdv-Agilon-Health-AGL-Long-at-2-24/)
Agilon Health
AGL
Pros:
Cons:
It's a gamble and I think it's a possibility this could drop near $1 in the near-term due to the Medicaid changes/fear... regardless, long-term, personal buy-zone at $2.36.
Targets in 2027
Agilon Health
AGLPros:
- Revenue consistently grew from 2019 ($794 million) to 2024 ($6.06 billion). Expected to reach $9.16 billion by 2028.
- Current debt-to-equity ratio 0.07 (very low)
- Sufficient cash reserves to fund operations and strategic initiatives
- Strong membership growth (659,000 in 2024, a 38% year-over-year increase)
- Recent insider buying ($2 - $3) and awarding of options
Cons:
- Rising medical costs - currently unprofitable and not forecast to become profitable over the next 3 years
- Medicare Advantage Membership issues with the new political administration
- No dividend
It's a gamble and I think it's a possibility this could drop near $1 in the near-term due to the Medicaid changes/fear... regardless, long-term, personal buy-zone at $2.36.
Targets in 2027
- $3.70 (+56.8%)
- $5.25 (+122.5%)
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.